公司概述
The Cooper Companies, Inc. is a specialized enterprise dedicated to the development, manufacturing, and marketing of contact lens wearers, with a broader operational scope that extends to medical instruments and supplies. Operating within the healthcare sector, the company functions specifically in the medical instruments and supplies industry, a domain characterized by high regulatory standards and consistent demand for patient care solutions. The entity operates at a substantial scale, boasting a market capitalization of $13.94 billion, annual revenue of $4.15 billion, and an workforce of 15,000 employees. These valuation and revenue figures indicate that the company holds a significant position within the healthcare ecosystem, reflecting a large-scale operational footprint that supports extensive distribution networks and product portfolios. The distinction between its primary focus on contact lens wearers and its broader industry classification suggests a diversified approach within the medical supplies niche, allowing it to capitalize on various segments of the healthcare market.
财务健康
The company reported a trailing twelve-month revenue of $4.15 billion and generated net income of $401.40 million, while achieving an EBITDA of $1.10 billion. The substantial gap between the $4.15 billion in revenue and the $401.40 million in net income reveals a cost structure where operating expenses, taxes, and interest obligations consume approximately 90.3% of total sales, indicating a high-cost environment typical of manufacturing and regulatory-heavy industries. The enterprise produced $367.09 million in free cash flow, a metric that signifies strong financial flexibility to fund operations, service debt, or pursue strategic acquisitions without relying solely on external capital markets. Profitability is assessed through three key margins: a gross margin of 65.4% highlights the high value added per unit sold before overhead, an operating margin of 20.8% demonstrates effective control over selling, general, and administrative costs, and a profit margin of 9.7% reflects the final return to shareholders after all expenses. Liquidity and leverage are evident in the balance sheet, where cash holdings of $124.90 million are significantly lower than total debt of $2.78 billion, and the debt-to-equity ratio stands at 33.20, suggesting a leveraged capital structure. Short-term liquidity is supported by a current ratio of 1.34, which indicates the company possesses sufficient current assets to cover its current liabilities, though the buffer is relatively modest. Management effectiveness is measured by a return on equity of 4.9% and a return on assets of 3.6%, figures that reveal the efficiency of capital deployment and asset utilization relative to the industry average.
估值评估
Valuation multiples provide insight into market expectations, with the trailing P/E ratio at 35.55 and a forward P/E of 14.24. The significant disparity between the trailing and forward P/E ratios implies that the market anticipates a substantial increase in earnings over the coming year, driven by the reported 26.9% earnings growth. The price-to-book ratio is recorded at 1.67, indicating that the market prices the company at a 67% premium over its book value, reflecting intangible assets or future growth potential not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 3.36 and an EV/EBITDA of 15.10, which suggest that the company is valued based on both sales generation and earnings power, providing a comprehensive view of its pricing relative to peers. Price momentum is observed within a 52-week range defined by a high of $89.83 and a low of $61.78, where the current price position relative to this range must be interpreted in the context of the forward P/E compression. The stock exhibits a beta of 1.07, which indicates that price volatility is slightly higher than the broader market, suggesting that the stock tends to move more aggressively than the general index during periods of market fluctuation.
Growth & Income
The company demonstrates robust expansion with revenue growth of 6.2% year-over-year and earnings growth of 26.9% year-over-year. The fact that earnings are growing at a rate nearly four times faster than revenue implies significant operational leverage and efficiency improvements that are translating into disproportionate profit increases. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that the company retains all earnings to reinvest into growth initiatives rather than distributing cash to shareholders. This retention strategy aligns with the forward P/E of 14.24, suggesting that the market values the company based on future capital appreciation rather than current yield. The overall growth and income profile is characterized by high capital reinvestment and accelerated earnings expansion, positioning the company for future scalability within the medical instruments sector.